Tweetovi

Blokirali ste korisnika/cu @OliXPharmaceut1

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @OliXPharmaceut1

  1. will be attending BIO International Convention 2019 in on June 3 - 6.

    Poništi
  2. OliX Pharmaceuticals (KOSDAQ: 226950) gives the Poster Presentation with Updated Data from ongoing Wet & Dry Preclinical studies of in the model of Rhesus Monkeys at in San Diego on May 23.

    Poništi
  3. Our CEO, DONG-KI LEE, PHD, will be presenting at Spring International symposium 2019 in Seoul on May 17. "RNAi Therapeutics Development Using Asymmetric siRNAs" Theme: Emerging Issues in Human Health and Toxicology Learn more:

    Poništi
  4. OliX Pharmaceuticals Expands Ocular Disease Pipeline; Adds OLX304A for the Treatment of Retinitis Pigmentosa. Learn more:

    Poništi
  5. We are very pleased to announce that Harvard retina specialist Dr. Vavvas has joined our SAB. Learn more:

    Poništi
  6. OliX Pharmaceuticals Announces The Ophthalmologist Demetrios G. Vavvas, M.D., Ph.D., to join Scientific Advisory Board. Learn more:

    Poništi
  7. OliX will give a poster presentation that includes updated data from ongoing Wet and Dry AMD preclinical studies of OLX301A at US in Manchester Grand Hyatt, San Diego, CA on May 20-23, 2019.

    Poništi
  8. Celebrating License and Collaboration Agreement with Théa

    Poništi
  9. Celebrating License and Collaboration Agreement with Théa

    Poništi
  10. Théa and OliX Announce Collaboration to Develop RNAi Therapies for the Treatment of AMD. Learn more:

    Poništi
  11. Understanding cp-asiRNA (cell penetrating asymmetric siRNA)

    Poništi
  12. Hurdles in Therapeutic Development? activation by leads to extensive retinal degeneration. But, short RNA duplex such as cp-asiRNA of , does not activate TLR3, thus should be a safer platform for therapeutics. 2019

    Poništi
  13. Celebrating our 9 year anniversary today!

    Poništi
  14. Celebrating our 9 year anniversary today!

    Poništi
  15. Poništi
  16. Our CEO, DONG-KI LEE, PHD, will be presenting at in Tokyo on February 28. "Asymmetric Targeting and Disorders" Track: Strategies You can learn more here:

    Poništi
  17. Poništi
  18. OliX's Core Values, cp-asiRNA platform technology

    Poništi
  19. 5th International Conference on Therapeutics with

    Poništi
  20. OliX’s therapy gets approval for phase 2 trials

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·